Antitumor compounds targeting VDACs are beginning to emerge, and VDAC–tubulin antagonists could become a new generation of metabolism-oriented cancer chemotherapy drugs [48,49], with statins likely to be one of the candidates. This evidence concerns the gene VDAC1 and cancer.